Biomarker & Intervention Discovery

Neck Pain (Chronic)

This page lists 6 druggable gene targets and 11 recent clinical trials for Neck Pain (Chronic), with each agent ranked by the strength of its evidence (clinical, mechanistic or correlative). Sources are linked so you can check every claim.

Disease Overview

Spontaneous remission
Not established
Best-intervention remission
—
Gap size
—
Primary barrier
—

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

GRIN1 183IL6 173NGF 9PTGS2 299SCN9A 271TRPV1 160
Therapeutic Agent Effect Direction Evidence Tier Potency Source
COMPOUND 53 [PMID: 33038794] ↑ activates Mechanistic
PAREGORIC ? unclear Mechanistic
STING AGONIST 2 ↑ activates Mechanistic
LATREPIRDINE ? unclear Mechanistic
CNS-5161 ↓ inhibits Mechanistic
MEMANTINE HYDROCHLORIDE ~ modulates Mechanistic
LANICEMINE ↓ inhibits Mechanistic
ULEVOSTINAG ↑ activates Mechanistic
ELIPRODIL ? unclear Mechanistic
NBQX ? unclear Mechanistic
RAPASTINEL ? unclear Mechanistic
DEXANABINOL ? unclear Mechanistic
NEBOGLAMINE ~ modulates Mechanistic
HALOPERIDOL DECANOATE ? unclear Mechanistic
ORPHENADRINE ? unclear Mechanistic
GW468816 ↓ inhibits Mechanistic
ACAMPROSATE CALCIUM ↓ inhibits Mechanistic
AMANTADINE HYDROCHLORIDE ↓ inhibits Mechanistic
H-151 ↓ inhibits Mechanistic
D-SERINE ? unclear Mechanistic
AZD8108 ↓ inhibits Mechanistic
KETAMINE HYDROCHLORIDE ~ modulates Mechanistic
DELUCEMINE ↓ inhibits Mechanistic
EVT-101 ↓ inhibits Mechanistic
MSA-2 ↑ activates Mechanistic
ESKETAMINE HYDROCHLORIDE ? unclear Mechanistic
2'3'-CGAMP ↑ activates Mechanistic
COMPOUND 40 [PMID: 33470814] ↑ activates Mechanistic
PHILANTHOTOXIN 343 ? unclear Mechanistic
FELBAMATE ↓ inhibits Mechanistic
INDANTADOL ↓ inhibits Mechanistic
STING AGONIST 3 ↑ activates Mechanistic
ORPHENADRINE HYDROCHLORIDE ↓ inhibits Mechanistic
CYCLOSERINE ? unclear Mechanistic
RADIPRODIL ↓ inhibits Mechanistic
PERZINFOTEL ↓ inhibits Mechanistic
ESKETAMINE ~ modulates Mechanistic
ADU-S100 ↑ activates Mechanistic
RALFINAMIDE ↓ inhibits Mechanistic
SNX281 ↑ activates Mechanistic

Showing top 40 of 183 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
CISPLATIN ? unclear Mechanistic
ZILTIVEKIMAB ~ modulates Mechanistic
CHINESE HERBS ? unclear Mechanistic
PF-04236921 ↓ inhibits Mechanistic
MRA 003 US ↓ inhibits Mechanistic
SIGNAL TRANSDUCTION INHIBITOR ? unclear Mechanistic
BINETRAKIN ? unclear Mechanistic
IBUDILAST ? unclear Mechanistic
INSULIN, REGULAR, HUMAN ? unclear Mechanistic
SILTUXIMAB ↓ inhibits Mechanistic
METRONIDAZOLE ? unclear Mechanistic
CLAZAKIZUMAB ↓ inhibits Mechanistic
GALLIUM NITRATE ? unclear Mechanistic
INTERFERON ALFA-2B ? unclear Mechanistic
DULOXETINE HYDROCHLORIDE ? unclear Mechanistic
MEDI-5117 ↓ inhibits Mechanistic
GEMFIBROZIL ? unclear Mechanistic
BIAFINE CREAM ? unclear Mechanistic
ETANERCEPT ? unclear Mechanistic
ELSILIMOMAB ↓ inhibits Mechanistic
SAQUINAVIR ? unclear Mechanistic
INFLIXIMAB ? unclear Mechanistic
LINEZOLID ? unclear Mechanistic
IFOSFAMIDE ? unclear Mechanistic
OLOKIZUMAB ↓ inhibits Mechanistic
HMG-COA REDUCTASE INHIBITOR ? unclear Mechanistic
MIDOSTAURIN ? unclear Mechanistic
SELENIUM ? unclear Mechanistic
SIRUKUMAB ↓ inhibits Mechanistic
PEGINTERFERON ALFA-2B ? unclear Mechanistic
ECHINACEA PREPARATION ? unclear Mechanistic
ENZYME INHIBITOR ? unclear Mechanistic
FENOFIBRATE MICRONIZED ? unclear Mechanistic
VITAMIN K ? unclear Mechanistic
PEGINTERFERON ALFA-2A ? unclear Mechanistic
RIBAVIRIN ? unclear Mechanistic
VITAMIN A PALMITATE ? unclear Mechanistic
ARSENIC TRIOXIDE ? unclear Mechanistic
DIHYDROSPHINGOSINE ? unclear Mechanistic
LEVOFLOXACIN ANHYDROUS ? unclear Mechanistic

Showing top 40 of 173 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
MEDI-578 ↓ inhibits Mechanistic
CERE-110 ? unclear Mechanistic
FASINUMAB ↓ inhibits Mechanistic
TANEZUMAB ↓ inhibits Mechanistic
FRUNEVETMAB ~ modulates Mechanistic
FULRANUMAB ↓ inhibits Mechanistic
BEDINVETMAB ~ modulates Mechanistic
PG-110 ↓ inhibits Mechanistic
CHEMBL1397270 ↓ inhibits Mechanistic 1000.0 nM (IC50)
Therapeutic Agent Effect Direction Evidence Tier Potency Source
CARPROFEN ↓ inhibits Mechanistic 102.0 nM (IC50)
INDOMETHACIN SODIUM ↓ inhibits Mechanistic
DARBUFELONE ? unclear Mechanistic
MEFENAMIC ACID ↓ inhibits Mechanistic
MECLOFENAMATE SODIUM ↓ inhibits Mechanistic
DICLOFENAC SODIUM ↓ inhibits Mechanistic
CAPECITABINE ? unclear Mechanistic
PIRPROFEN ↓ inhibits Mechanistic
ESFLURBIPROFEN ↓ inhibits Mechanistic
SULFASALAZINE ↓ inhibits Mechanistic
BROMFENAC ? unclear Mechanistic
IBUPROFEN, SODIUM SALT ↓ inhibits Mechanistic
ALOXIPRIN ↓ inhibits Mechanistic
TENOXICAM ? unclear Mechanistic
FLURBIPROFEN ↓ inhibits Mechanistic
SALICYLIC ACID ? unclear Mechanistic
ATENOLOL ? unclear Mechanistic
DEXKETOPROFEN ↓ inhibits Mechanistic
ETORICOXIB ↓ inhibits Mechanistic
LUMIRACOXIB ↓ inhibits Mechanistic
SUPROFEN ↓ inhibits Mechanistic
NS-398 ? unclear Mechanistic
NABUMETONE ↓ inhibits Mechanistic
URSOLIC ACID ? unclear Mechanistic
IBUPROFEN LYSINE ↓ inhibits Mechanistic
ACECLOFENAC ↓ inhibits Mechanistic
IBUFENAC ↓ inhibits Mechanistic
BALSALAZIDE ? unclear Mechanistic
DIFLUNISAL ↓ inhibits Mechanistic
BALSALAZIDE DISODIUM ↓ inhibits Mechanistic
VACCINE ? unclear Mechanistic
KETOROLAC TROMETHAMINE ↓ inhibits Mechanistic
BENZYDAMINE HYDROCHLORIDE ↓ inhibits Mechanistic
TIAPROFENIC ACID ? unclear Mechanistic
RALOXIFENE HYDROCHLORIDE ? unclear Mechanistic
NAPROXCINOD ↓ inhibits Mechanistic
IGURATIMOD ↓ inhibits Mechanistic
ETODOLAC ↓ inhibits Mechanistic
DICLOFENAC ETALHYALURONATE SODIUM ↓ inhibits Mechanistic
ROFECOXIB ↓ inhibits Mechanistic 530.0 nM (IC50)

Showing top 40 of 299 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
MERETHOXYLLINE PROCAINE ↓ inhibits Mechanistic
ETIDOCAINE HYDROCHLORIDE ↓ inhibits Mechanistic
FOSPHENYTOIN ↓ inhibits Mechanistic
VERATRIDINE ↑ activates Mechanistic
ORPHENADRINE CITRATE ↓ inhibits Mechanistic
PHENACEMIDE ↓ inhibits Mechanistic
LACOSAMIDE ↓ inhibits Mechanistic
VIXOTRIGINE ↓ inhibits Mechanistic
DSP-2230 ↓ inhibits Mechanistic
SAXITOXIN ↓ inhibits Mechanistic
ESLICARBAZEPINE ACETATE ↓ inhibits Mechanistic
SAFINAMIDE ? unclear Mechanistic
LIDOCAINE ↓ inhibits Mechanistic
RILUZOLE ↓ inhibits Mechanistic
ROPIVACAINE HYDROCHLORIDE ↓ inhibits Mechanistic
FUNAPIDE ↓ inhibits Mechanistic
DYCLONINE HYDROCHLORIDE ↓ inhibits Mechanistic
EVENAMIDE ↓ inhibits Mechanistic
PROPOFOL ? unclear Mechanistic
AM-6120 ↓ inhibits Mechanistic
RG7893 ↓ inhibits Mechanistic
RG6029 ↓ inhibits Mechanistic
QUINIDINE SULFATE ↓ inhibits Mechanistic
ZONISAMIDE ↓ inhibits Mechanistic
NERISPIRDINE ↓ inhibits Mechanistic
RALFINAMIDE ↓ inhibits Mechanistic
DS-1971A ↓ inhibits Mechanistic
HEXYLCAINE HYDROCHLORIDE ↓ inhibits Mechanistic
MEPIVACAINE HYDROCHLORIDE ↓ inhibits Mechanistic
PROCAINAMIDE HYDROCHLORIDE ↓ inhibits Mechanistic
PROPAFENONE HYDROCHLORIDE ↓ inhibits Mechanistic
LIDOCAINE HYDROCHLORIDE ↓ inhibits Mechanistic
QUINIDINE GLUCONATE ↓ inhibits Mechanistic
PRILOCAINE ↓ inhibits Mechanistic
ETHOTOIN ↓ inhibits Mechanistic
PF-05089771 ↓ inhibits Mechanistic
DICHLOROBENZYL ALCOHOL ↓ inhibits Mechanistic
RANOLAZINE ? unclear Mechanistic
PRILOCAINE HYDROCHLORIDE ↓ inhibits Mechanistic
ORPHENADRINE HYDROCHLORIDE ↓ inhibits Mechanistic

Showing top 40 of 271 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
STREPTOZOCIN ? unclear Mechanistic
BENZYL ISOTHIOCYANATE ? unclear Mechanistic
ACETAMINOPHEN ↑ activates Mechanistic
POLYGODIAL ? unclear Mechanistic
PROPOFOL ? unclear Mechanistic
SAF312 ↓ inhibits Mechanistic
GRC-15300 ? unclear Mechanistic
AZD1386 ↓ inhibits Mechanistic
TIVANISIRAN ↓ inhibits Mechanistic
MAVATREP ↓ inhibits Mechanistic
MR-1817 ↓ inhibits Mechanistic
FERRUGINENE B ? unclear Mechanistic
CAPSAICIN ↑ activates Mechanistic 19.95 nM (EC50)
RECOMBINANT TUMOR NECROSIS FACTOR FAMILY PROTEIN ? unclear Mechanistic
PHENETHYLISOTHIOCYANATE ? unclear Mechanistic
VOACANGINE ? unclear Mechanistic
RESINIFERATOXIN ↑ activates Mechanistic 23.1 nM (Ki)
DWP05195 ↓ inhibits Mechanistic
XEN-D0501 ↓ inhibits Mechanistic
PAC-14028 ↓ inhibits Mechanistic
SB-705498 ↓ inhibits Mechanistic
MASOPROCOL ? unclear Mechanistic
ALLYL ISOTHIOCYANATE ? unclear Mechanistic
NGD-8243 ↓ inhibits Mechanistic
GRC-6211 ↓ inhibits Mechanistic
RESERPINE ? unclear Mechanistic
NABIXIMOLS ? unclear Mechanistic
A425619 ? unclear Mechanistic
PHE377 ↓ inhibits Mechanistic
ANTISENSE OLIGONUCLEOTIDES ? unclear Mechanistic
WORTMANNIN ? unclear Mechanistic
JTS-653 ↓ inhibits Mechanistic
LEVODOPA ? unclear Mechanistic
AMG517 ↓ inhibits Mechanistic
CAPSAZEPINE ? unclear Mechanistic 120.0 nM (Ki)
ZUCAPSAICIN ↑ activates Mechanistic
INDOMETHACIN ? unclear Mechanistic
CHEMBL:CHEMBL191534 ? unclear Mechanistic
ABT-102 ↓ inhibits Mechanistic
ISOPROPYL ISOTHIOCYANATE ? unclear Mechanistic

Showing top 40 of 160 agents ranked by evidence tier.


Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Neck Pain (Chronic): recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

NCT07462988 Phase: N/A Started: 2025-01-01

Neck pain is a common health problem in the general population. Approximately 71% of adults experience neck pain at some point in their lives, and its annual prevalence ranges between 30-50% in both the general and working populations. Although neck pain often resolves spontaneously within a few day...

NCT05605639 Phase: 4 Started: 2022-11-17

Neck pain frequently present comorbidities in peridiaphragmatic organs. The innervation of these organs include the phrenic nerve. It is known that peridiaphragmatic organs trigger referred pain in the neck area. As well, previous studies have shown that visceral disorders increase sensitization in ...

NCT03294785 Phase: N/A Started: 2017-10-18

A multi-center randomized controlled trial assessing the comparative effectiveness and cost-effectiveness of Chuna manual therapy for chronic neck pain

NCT07058636 Phase: N/A Started: 2025-04-03

Study Title: Evaluation of the Effectiveness of Adding Greater Occipital Nerve Block to Trigger Point Injection in Patients with Neck Pain Due to Upper Trapezius Trigger Points: A Single-Blind Randomized Controlled Trial Purpose of the Study: This study aims to evaluate whether adding a Greater Occi...

NCT05946837 Phase: 1 Started: 2023-08-29

The purpose of this study is to objectively assess lymphatic function before, during, and immediately after Neuroglide treatment in lower trunk and leg lymphatic vessels, torso, axillary regions, inguinal regions, upper extremities, and cervical/neck and to determine any VAS (Visual Analog Scale, a ...

NCT04378959 Phase: N/A Started: 2021-02-01

In this randomized, double-blind, placebo-controlled crossover study, up to 84 patients with non-radicular neck pain will be allocated in a 1:1 ratio to receive up to 3 topical lidocaine or placebo patches, to be applied 12 hours per day. At the end of 4 weeks, patients will return for patients' pos...

NCT02814565 Phase: 3 Started: 2016-10-12

The purpose of this study was to assess the effect of cyclobenzaprine hydrochloride (HCl) extended release (CER) 15 mg capsule once daily in participants with muscle spasms associated with acute painful musculoskeletal conditions.

NCT01561209 Phase: 4 Started: 2012-03

The objective of this prospective randomized and controlled study is to evaluate the efficacy and safety of low dose of amitriptyline (5 mg) in the management of chronic neck pain.

NCT01922466 Phase: 2 Started: 2013-07

The purpose of this study is to evaluate the efficacy and safety of east-west collaborative treatment using bee venom acupuncture and NSAIDs on pain intensity, functional status and quality of life of patients with chronic cervicalgia

NCT00429624 Phase: N/A Started: 1994-09

The purpose of this study is to determine whether chiropractic manipulation or medical therapy is effective in the treatment of chronic neck pain.

NCT01716377 Phase: 2 Started: 2012-10

Purpose: The purpose of this study is to demonstrate the potential efficacy of venlafaxine administration in reducing acute and chronic musculoskeletal pain in individuals presenting to the ED for evaluation after motor vehicle collision. Participants: Participants will consist of 60 patients betwee...


Agents Found By Disease-Level Search

Searched directly from “Neck Pain (Chronic)” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 6-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."